Overview

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer

Status:
RECRUITING

Trial end date:
2032-07-05

Target enrollment:

Participant gender:

Summary

This clinical trial is designed to assess the efficacy and safety of trastuzumab deruxtecan (T-DXd; Enhertu) in combination with pembrolizumab versus platinum-based chemotherapy in combination with pembrolizumab in participants with no prior therapy for locally advanced unresectable or metastatic non-squamous NSCLC, whose tumors have HER2-overexpressing and PD-L1 TPS \<50% without known AGA that have locally available therapies targeting their AGAs in first-line advanced/metastatic setting.

Phase:

PHASE3

Details

Lead Sponsor:

Daiichi Sankyo

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

Drug Therapy
pembrolizumab
Pemetrexed
trastuzumab deruxtecan